Julia LeCher

Dr. Julia LeCher

Emory University, Atlanta, Georgia, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FAfranck amblard
franck amblard
JLJulia LeCher
Julia LeCher
RDRamyani De
Ramyani De
SGShu Ling Goh
Shu Ling Goh
CLChengwei Li
Chengwei Li
RSRaymond Schinazi
Raymond Schinazi
Coronavirus disease 2019 (COVID-19) is an emerging global pandemic with severe morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Molnupiravir, an ester prodrug form of N4-hydroxycytidine (NHC), was recently emergency-use approved for the treatment of early SARS-CoV-2 infections. Herein, we report the synthesis and evaluation of a series of novel NHC analogs.

4 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JLJi-Hoon Lee
Ji-Hoon Lee
JLJulia LeCher
Julia LeCher
EPEric Parigoris
Eric Parigoris
NSNoriyuki Shinagawa
Noriyuki Shinagawa
JSJason Sentosa
Jason Sentosa
STShuichi Takayama
Shuichi Takayama
While breakthroughs with organoids have emerged as next-generation in vitro tools, standardization for drug discovery remains a challenge. This work introduces human airway organoids with reversed biopolarity (AORBs), cultured and analyzed in a high-throughput, single-organoid-per-well format, enabling milestones towards standardization. AORBs exhibit a spatio-temporally stable apical-out morphology, facilitating high-yield direct intact-organoid virus infection. Single-cell RNA sequencing and immunohistochemistry confirm the physiologically relevant recapitulation of differentiated human airway epithelia. The cellular tropism of five severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains along with host response differences between Delta, Washington, and Omicron variants, as observed in transcriptomic profiles, also suggest clinical relevance. Dose-response analysis of three well-studied SARS-CoV-2 antiviral compounds (remdesivir, bemnifosbuvir, and nirmatrelvir) demonstrates that AORBs efficiently predict human efficacy, comparable to gold-standard air-liquid interface cultures, but with higher throughput (∼10-fold) and fewer cells (∼100-fold). This combination of throughput and relevance allows AORBs to robustly detect false negative results in efficacy, preventing irretrievable loss of promising lead compounds. While this work leverages the SARS-CoV-2 study as a proof-of-concept application, the standardization capacity of AORB holds broader implications in line with regulatory efforts to push alternatives to animal studies.

3 October 2025 in Science Advances
Verified
Journal Article
Open access
FAFranck Amblard
Franck Amblard
MKMahesh Kasthuri
Mahesh Kasthuri
JLJulia LeCher
Julia LeCher
STSijia Tao
Sijia Tao
RDRamyani De
Ramyani De
RSRaymond Schinazi
Raymond Schinazi
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 epidemic is relatively under control due to the rapid development and deployment of vaccines and a few drugs. However, challenges persist, as new variants and issues with vaccine durability may compromise their effectiveness. Here, we report the discovery and evaluation of 1′-cyanocytidine (CNC), a nontoxic, next-generation nucleoside analog that displays submicromolar inhibition of SARS-CoV-2 replication in various cell and 3D HAE-ALI primary culture systems. Intracellularly, CNC is metabolized to its active 5′-triphosphate form (CNC-TP), targeting the viral RNA–dependent RNA polymerase. Pre–steady-state kinetic analysis revealed CNC-TP is a reversible, competitive inhibitor. The 5′-isobutyryl ester prodrug of CNC (CN iBu C), which rapidly converts to CNC in mouse and hamster plasma, substantially reduced viral RNA levels and lung infectious virus titers in a Syrian hamster model after intraperitoneal and oral dosing. With favorable pharmacokinetics, bioavailability, and safety profiles, CNC and CN iBu C represent promising candidates for SARS-CoV-2 therapy.

16 February 2023 in Viruses
Verified
Journal Article
Open access
PDF file
NBNicolas G. Biteau
Nicolas G. Biteau
SASarah A. Amichai
Sarah A. Amichai
NANiloufar Azadi
Niloufar Azadi
RDRamyani De
Ramyani De
JDJessica Downs-Bowen
Jessica Downs-Bowen
FAfranck amblard
franck amblard
Over the past decades, both 4′-modified nucleoside and carbocyclic nucleoside analogs have been under the spotlight as several compounds from either family showed anti-HIV, HCV, RSV or SARS-CoV-2 activity. Herein, we designed compounds combining these two features and report the synthesis of a series of novel 4′-substituted carbocyclic uracil derivatives along with their corresponding monophosphate prodrugs. These compounds were successfully prepared in 19 to 22 steps from the commercially available (-)-Vince lactam and were evaluated against a panel of RNA viruses including SARS-CoV-2, influenza A/B viruses and norovirus.

7 May 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
JLJulia LeCher
Julia LeCher
VCVivian Vasconcelos Costa
Vivian Vasconcelos Costa
LRLauren N. Rust
Lauren N. Rust
LBLeda C. Bassit
Leda C. Bassit
DPDharmeshkumar Patel
Dharmeshkumar Patel
RSRaymond Schinazi
Raymond Schinazi
Yellow fever virus (YFV) is a deadly zoonotic flavivirus endemic in tropical/sub-tropical Africa and South America transmitted by mosquito vector ( Aedes aegypti ; Haemagogus leucocelaenus ) to humans and non-human primates. There are no approved antiviral agents for YFV. We previously identified 7-deaza-7-fluoro-2′-C-methyladenosine (DFA) with anti-YFV activity. Interestingly, DFA exhibits pan-activity in vitro against flaviviruses, such as dengue, Japanese encephalitis, Zika, and hepatitis C. This study aimed to expand DFA’s anti-flavivirus profile. DFA exhibited potent sub-micromolar anti-YFV activity in vitro against both the vaccine strain (YFV-17D) and a viscerotropic clinical YFV isolate (DakH1279) concomitantly with low cellular cytotoxicity and no notable mitochondrial toxicity. In vivo , efficacy was assessed against both YFV-17DD and a human clinical isolate in A129 and AG129 mouse flavivirus infection models, respectively. DFA significantly reduced virus replication in the livers of YFV-infected mice and the hallmarks of YFV-induced liver damage, including alanine transaminase levels and indocyanine green clearance. Collectively, this work identifies DFA as a potent YFV inhibitor and lays the groundwork for further therapeutic development as a YFV and, potentially, pan-flavivirus therapeutic.

22 October 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
JLJulia LeCher
Julia LeCher
KZKeivan Zandi
Keivan Zandi
VCVivian V. Costa
Vivian V. Costa
FAfranck amblard
franck amblard
STSijia Tao
Sijia Tao
RSRaymond Schinazi
Raymond Schinazi
Yellow fever virus (YFV) is a potentially lethal, zoonotic, blood-borne flavivirus transmitted to humans and non-human primates by mosquitoes. Owing to multiple deadly epidemics, the WHO classifies YFV as a “high impact, high threat disease” with resurgent epidemic potential. At present, there are no approved antiviral therapies to combat YFV infection. Herein we report on 2′-halogen-modified nucleoside analogs as potential anti-YFV agents. Of 11 compounds evaluated, three showed great promise with low toxicity, high intracellular metabolism into the active nucleoside triphosphate form, and sub-micromolar anti-YFV activity. Notably, we investigated a 2′-fluoro,2′-bromouridine phosphate prodrug (C9), a known anti-HCV agent with good stability in human blood and favorable metabolism. Predictive modeling revealed that C9 could readily bind the active site of the YFV RdRp, conferring its anti-YFV activity. C9 displayed potent anti-YFV activity in primary human macrophages, 3D hepatocyte spheroids, and in mice. In an A129 murine model, shortly after infection, C9 significantly reduced YFV replication and protected against YFV-induced liver inflammation and pathology with no adverse effects. Collectively, this work identifies a potent new anti-YFV agent with strong therapeutic promise.